You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
The appropriate dose and cost of iron replacement therapy in patients with IBD
  1. Rui Dong,
  2. Shan Zheng,
  3. Gong Chen
  1. Department of Pediatric Surgery, Children's Hospital of Fudan University, and Key Laboratory of Neonatal Disease, Ministry of Health, Shanghai, China
  1. Correspondence to Dr Rui Dong, Department of Pediatric Surgery, Children's Hospital of Fudan University, and Key Laboratory of Neonatal Disease, Ministry of Health, 399 Wan Yuan Road, Shanghai 201102, China; dongrui_1982{at}126.com

https://doi.org/10.1136/gutjnl-2016-311725

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by Lee et al,1 who performed an open-label clinical trial to compare the effects of per os (PO) versus intravenous iron replacement therapy (IRT) for iron deficiency in patients with IBD. They concluded that IRT in patients with iron deficiency or anaemia induced significant shifts in bacterial community structure and metabolite landscape in faeces, and PO iron therapy affected the presence of specific molecular bacterial species. These are impressive findings that raise two important issues.

    First, Lee et al 1 enrolled participants with Crohn’s disease (n=31), UC (n=22) and non-IBD control anaemic subjects (n=19) for IRT intervention 3 months PO iron sulfate or intravenous iron sucrose. PO participants …

    View Full Text